NO20053726L - Forbindelser med prolyloligopeptidase-hemmende aktivitet - Google Patents

Forbindelser med prolyloligopeptidase-hemmende aktivitet

Info

Publication number
NO20053726L
NO20053726L NO20053726A NO20053726A NO20053726L NO 20053726 L NO20053726 L NO 20053726L NO 20053726 A NO20053726 A NO 20053726A NO 20053726 A NO20053726 A NO 20053726A NO 20053726 L NO20053726 L NO 20053726L
Authority
NO
Norway
Prior art keywords
compounds
prolyl oligopeptidase
inhibitory activity
formula
treatment
Prior art date
Application number
NO20053726A
Other languages
English (en)
Other versions
NO20053726D0 (no
Inventor
Tomi Jarvinen
Jouko Vepsalainen
Johannes A M Christiaans
Elina Jahro
Pekka Mannisto
Taija Saarinen
Jukka Ghynter
Erik Wallen
Markus Forsberg
Antti Poso
Jarkko Venalainen
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of NO20053726D0 publication Critical patent/NO20053726D0/no
Publication of NO20053726L publication Critical patent/NO20053726L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Den foreliggende oppfinnelsen tilveiebringer en forbindelse med formel (I) hvori i formelen X, Ri, R2 og R3 er som definert i krav 1, eller et farmasøytisk akseptabelt salt eller en ester derav, anvendbar som en prolyloligopeptidaseinhibitor. Forbindelsene med formel (I) kan anvendes for behandling av sykdommer eller tilstander hvor prolyloligopeptidaseinhibitorer er indikert å være effektive, for eksempel for behandling av nevrodegenerative sykdommer så som Alzheimers sykdom og senil demens.
NO20053726A 2003-01-03 2005-08-03 Forbindelser med prolyloligopeptidase-hemmende aktivitet NO20053726L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20030014A FI20030014A0 (fi) 2003-01-03 2003-01-03 Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä
PCT/FI2004/000001 WO2004060862A2 (en) 2003-01-03 2004-01-02 Compounds having prolyl oligopeptidase inhibitory activity

Publications (2)

Publication Number Publication Date
NO20053726D0 NO20053726D0 (no) 2005-08-03
NO20053726L true NO20053726L (no) 2005-09-28

Family

ID=8565256

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053726A NO20053726L (no) 2003-01-03 2005-08-03 Forbindelser med prolyloligopeptidase-hemmende aktivitet

Country Status (18)

Country Link
US (1) US20060229254A1 (no)
EP (1) EP1581489A2 (no)
JP (1) JP2006516557A (no)
KR (1) KR20060027789A (no)
CN (1) CN1747930A (no)
AU (1) AU2004203788A1 (no)
BR (1) BRPI0406618A (no)
CA (1) CA2511856A1 (no)
EA (1) EA010022B1 (no)
FI (1) FI20030014A0 (no)
HR (1) HRP20050693A2 (no)
IS (1) IS7963A (no)
MX (1) MXPA05007262A (no)
NO (1) NO20053726L (no)
PL (1) PL378329A1 (no)
RS (1) RS20050514A (no)
WO (1) WO2004060862A2 (no)
ZA (1) ZA200505183B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS56751B1 (sr) * 2009-12-18 2018-04-30 Ogeda Sa Derivati pirolidin karboksilne kiseline kao agonisti g-protein spojenog receptora 43 (gpr43), farmaceutska kompozicija i postupci za upotrebu u lečenju metaboličkih poremećaja
EP2730571A1 (en) 2012-11-12 2014-05-14 Universitat De Barcelona 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives
EP3610872A1 (en) 2013-11-27 2020-02-19 Epics Therapeutics Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
KR101913506B1 (ko) * 2017-07-18 2018-10-30 경상대학교산학협력단 프롤릴 올리고펩티다아제 억제제를 유효성분으로 함유하는 퇴행성 뇌질환 예방 또는 치료용 조성물
WO2022008477A1 (en) 2020-07-07 2022-01-13 Accure Therapeutics, S.L. 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4483991A (en) * 1983-01-17 1984-11-20 American Home Products Corporation Hypotensive agents
EP0201741B1 (en) * 1985-04-16 1991-07-31 Suntory Limited Dipeptide derivatives, processes for preparing them, pharmaceutical composition and use
CA1320734C (en) * 1986-02-04 1993-07-27 Suntory Limited Pyrrolidineamide derivative of acylamino acid and pharmaceutical composition containing the same
JPH0696563B2 (ja) * 1986-02-04 1994-11-30 サントリー株式会社 アシルアミノ酸誘導体、その製法並びに用途
JP2511605B2 (ja) * 1990-06-04 1996-07-03 ファイザー・インコーポレーテッド 芳香性ピロリジンおよびチアゾリヂンアミド類
AU643300B2 (en) * 1990-06-07 1993-11-11 Zeria Pharmaceutical Co., Ltd. Novel arylalkanoylamine derivative and drug containing the same
EP0915088B1 (en) * 1997-10-31 2002-09-18 F. Hoffmann-La Roche Ag D-Proline derivatives

Also Published As

Publication number Publication date
ZA200505183B (en) 2006-04-26
EP1581489A2 (en) 2005-10-05
US20060229254A1 (en) 2006-10-12
EA200501083A1 (ru) 2006-02-24
IS7963A (is) 2005-07-28
MXPA05007262A (es) 2005-09-08
CN1747930A (zh) 2006-03-15
HRP20050693A2 (en) 2005-10-31
JP2006516557A (ja) 2006-07-06
NO20053726D0 (no) 2005-08-03
FI20030014A0 (fi) 2003-01-03
KR20060027789A (ko) 2006-03-28
CA2511856A1 (en) 2004-07-22
WO2004060862A3 (en) 2004-11-25
WO2004060862A2 (en) 2004-07-22
PL378329A1 (pl) 2006-03-20
EA010022B1 (ru) 2008-06-30
BRPI0406618A (pt) 2005-12-06
AU2004203788A1 (en) 2004-07-22
RS20050514A (en) 2007-12-31

Similar Documents

Publication Publication Date Title
NO20053627L (no) Malonamidderivater som gamma-sekretase inhibitorer
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
NO20051189L (no) 1,3-diamino-2-hydroksypropan prodrogederivater
ATE368031T1 (de) Neue gamma secretase inhibitoren
NO20063294L (no) Heterosykliske aspartylproteaseinhibitorer
TW200512195A (en) Benzamide 2-hydroxy-3-diaminoalkanes
NO20045137L (no) Diketohydrazinderivatforbindelser og legemidler inneholdende forbindelser som aktiv ingrediens
NO20055979L (no) Sykliske sulfonamider for inhibering av gamma-secretase
WO2004087699A3 (en) Thiazoles useful as inhibitors of protein kinases
NO20073099L (no) Amino-imidazoloner for inhibering av beta-sekretase
NO20052487L (no) 1-(4-benzyl-piperazin-1-yl)-3-fenyl-propenonderivater.
NO20051600L (no) 1,4-disubstituerte piperidinderivater og anvendelse derav som 11-betaHSD1 inhibitorer
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
NO20050741L (no) Ny fremgangsmate for syntesen og ny krystallinsk form av agomelatin og farmasoytiske sammensetninger inneholdende den
NO20051239L (no) Acetyl 2-hydrolsy-1.3 diaminoalkaner
WO2005065195A3 (en) Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease
NO20081843L (no) Farmasoytisk sammensetning for forbedret kognitiv funksjon
DE602004011255D1 (de) Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
NO20041631L (no) Piperazinderivater med CCR1 reseptor antagonist
MXPA04002785A (es) Aminas sustituidas para tratamiento de enfermedad de alzheimer.
ATE451922T1 (de) Verwendung von thiazolidinon-derivaten zur behandlung von festen tumoren
NO20060268L (no) Enalapril-nitroksyderivater og beslektede forbindelser som ACE-inhibitorer for behandling av kardiovaskulaere sykdommer
NO20053726L (no) Forbindelser med prolyloligopeptidase-hemmende aktivitet
WO2008036316A3 (en) Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application